NICE Recommends Mepolizumab for Uncontrolled COPD
NICE has recommended mepolizumab as an add-on treatment for adults with uncontrolled COPD and raised blood eosinophils. This biologic therapy aims to reduce exacerbations and improve patient outcomes. The decision is expected to benefit approximately 30,000 individuals in England suffering from this condition.
- ▪NICE recommends mepolizumab for uncontrolled COPD with raised blood eosinophils in adults.
- ▪Mepolizumab is administered subcutaneously every 4 weeks and targets interleukin-5 to reduce eosinophil levels.
- ▪Clinical trials showed that mepolizumab plus triple therapy significantly reduced moderate or severe exacerbations compared to triple therapy alone.
Opening excerpt (first ~120 words) tap to expand
The National Institute for Health and Care Excellence (NICE) has recommended mepolizumab for the treatment of chronic obstructive pulmonary disease (COPD). In its final draft guidance, NICE said that mepolizumab was recommended as an add-on maintenance treatment option for uncontrolled COPD with raised blood eosinophils in adults, if they were receiving triple inhaler therapy — including an inhaled corticosteroid (ICS), a long-acting beta-2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). Uncontrolled COPD is defined as one or more severe exacerbations or two or more moderate exacerbations in the previous 12 months.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
